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Abstract
Objectives To study the time-to-recurrence and duration
of response in non-muscle invasive bladder cancer
(NMIBC) patients, with a complete ablative response after
intravesical apaziquone instillations.
Methods Transurethral resection of bladder tumour(s)
(TURBT) was performed in patients with multiple pTa-T1
G1-2 urothelial cell carcinoma (UCC) of the bladder, with
the exception of one marker lesion of 0.5–1.0 cm. Intraves-
ical apaziquone was administered at weekly intervals for
six consecutive weeks, without maintenance instillations. A
histological conWrmed response was obtained 2–4 weeks
after the last instillation. Routine follow-up (FU) was car-
ried out at 6, 9, 12, 18 and 24 months from the Wrst apaziqu-
one instillation.
Results At 3 months FU 31 of 46 patients (67.4%) had a
complete response (CR) to ablative treatment. Side-eVects
on the long-term were only mild. Two CR patients dropped
out during FU. On intention-to-treat (ITT) analysis 49.5%
of the CR patients were recurrence-free at 24 months FU,
with a median duration of response of 18 months. Of 15 no
response (NR) patients, only two received additional pro-
phylactic instillations after TURBT. On ITT-analysis
26.7% of the NR patients were recurrence-free (log rank
test, P = 0.155). The overall recurrence-free survival was
39% (18 of 46 patients) at 24 months FU.
Conclusions The CR of the marker lesion in 67% of
patients was followed by a recurrence-free rate of 56.5% at
1-year FU, and 49.5% at 2-year FU. These long-term
results are good in comparison with the results of other
ablative studies.
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Abbreviations
BCG Bacille Calmette-Guérin
CIS Carcinoma in situ
CR Complete response
DTD Deoxythymidine-diaphorase
EO9 Apaziquone, EOquin®
EORTC European Organisation for Research and 
Treatment of Cancer
FU Follow-up
ITT Intention to treat analysis
NCI-CTC National Cancer Institute-Common Toxicity
Criteria
NMIBC Non-muscle invasive bladder cancer
NR No response
TURBT Transurethral resection of bladder tumour(s)
UCC Urothelial cell carcinoma
WHO World Health Organization
Introduction
The initial treatment of non-muscle invasive bladder cancer
(NMIBC) consists of complete transurethral resection of
the bladder tumour(s) (TURBT), followed by adjuvant
intravesical instillations of chemotherapy or immunother-
apy [1, 2]. Choice of type and schedule of adjuvant treat-
ment depends on prognostic factors that are used to
determine patient’s risk of NMIBC recurrence, and pro-
gression to muscle invasive disease, as for example the fac-
tors used in the European Organisation for Research and
Treatment of Cancer (EORTC) risk Table [3]. According to
these tables, the calculated probabilities for recurrence of
disease range from 15–61% at 1 year to 31–78% at 5 years,
and for progression from <1–17% at 1 year to <1–45% at
5 years. These probabilities of recurrence and progression
of disease indicate that current treatment regimens are sub-
optimal and demonstrate a clear need for more eVective
treatment of NMIBC.
Apaziquone is a derivative of the clinically used mito-
mycin-C(MMC). It is a novel fully synthetic bioreductive
alkylating indoloquinone pro-drug, that is converted to
cytotoxic species after enzymatic activation [4]. The
enzyme deoxythymidine-diaphorase (DTD) plays a promi-
nent role in the activation of apaziquone under aerobic con-
ditions, but apaziquone is also cytotoxic under hypoxic
conditions, also in cells with low DTD activity [5]. In pre-
clinical research, the concentration of apaziquone needed to
achieve 50% cell death was 6–78 times lower than the con-
centration of MMC, depending on the urothelial cell carci-
noma (UCC) cell line used [6].
In the initial eYcacy analysis of this phase II study with
EO9/EOquin (apaziquone formulated for intravesical
administration) for NMIBC a histological complete
response (CR) of the marker lesion in 67% of the patients
was demonstrated after six weekly apaziquone instillations,
with local side-eVects comparable to side-eVects due to
other chemo-instillations [7]. However, the follow-up (FU)
period was relatively short. Recently, Jain et al., reported
long-term FU of eight phase I study patients treated with
apaziquone [8], with a median time to Wrst recurrence of
21.5 months [9] (R. Puri, personal communication).
In the present study, we report the 2-year eYcacy results
of intravesical apaziquone after a CR for patients with
intermediate- and high-risk NMIBC.
Methods
Seven hospitals participated in this prospective phase II
trial. The study was conducted in accordance with the ethi-
cal standards of the Declaration of Helsinki amended ver-
sion 1989. The study was approved by the individual
institutional review board/ethical committee of each partic-
ipating hospital.
Patient selection
Patients with multiple (·10) histologically conWrmed Ta-
T1 G1-G2 UCC of the bladder were included. All visible
lesions were completely resected with TURBT as evi-
denced by the inclusion of muscle tissue in the resected
specimens, conWrmed by pathology. Additionally, random
biopsies were taken, and in case of areas suspect for carci-
noma in situ (CIS) also targeted biopsies. One marker
lesion measuring between 0.5 and 1.0 cm in greatest diame-
ter was left intact. The resection loop (0.6 cm) was used as
reference for tumour size estimation. Images of the site of
the marker lesion were recorded.
Patients gave a written informed consent before being
enrolled in the study. The patients with a likelihood of mus-
cle invasive disease (¸T2), G3 tumours or CIS were
excluded. Further inclusion and exclusion criteria have
been described in detail before [7].
Treatment
Intravesical instillations were started 14 § 3 days after
TURBT. Apaziquone 4 mg in 40 ml of instillate (Spectrum
Pharmaceuticals Inc., Irvine, California) was administered
at weekly intervals for six consecutive weeks. Apaziquone
was retained in the bladder for 1 h. When local side-eVects
occurred, treatment was delayed or the dose of apaziquone
adjusted to 2 mg/40 ml.World J Urol (2009) 27:337–342 339
123
Patient evaluation and follow-up
Subsequent to the last instillation 2–4 weeks later, the marker
lesion response was evaluated under anaesthesia. Complete
disappearance of the marker lesion as judged by visual
inspection was conWrmed by biopsy (CR). When the tumour
persisted, the marker lesion was resected [no response (NR)].
Partial responses were not evaluated in view of the limita-
tions in tumour measurements. The tumours were classiWed
according to standard recommendations [10, 11].
The presence, severity and frequency of adverse events
were assessed in the weeks following apaziquone adminis-
tration, and deWned according to the National Cancer Insti-
tute (NCI) Common Toxicity Criteria (CTC) Version 3.0.
Further details of FU during treatment have been described
in detail before [7].
The patients with NR remained in the study, and for
these patients the decision to give additional treatment was
left to the discretion of the investigator. A routine FU was
carried out at 6, 9, 12, 18 and 24 months from the Wrst apa-
ziquone instillation. Evaluations consisted of urea and cre-
atinine assessment, urinalysis, urine cytology and
cystoscopy. The presence of recurrent UCC had to be con-
Wrmed with biopsies.
Statistical considerations
For the primary analysis we assumed a CR rate of approxi-
mately 50%. With a power of 80%,  error of 5% and 
error of 20%, and to reject with the same power a response
rate of <30%, 44 patients needed to be enrolled.
The patients were followed for 24 months or until disease
recurrence or progression was observed. Intention-to-treat
analysis (ITT) was performed on all patients with a CR at
3 months FU. The recurrence-free rate was deWned as the per-
centage of CR patients with no recurrence in FU at a certain
point of time. The duration of disease-free interval was esti-
mated according to the Kaplan–Meier method. The progres-
sion of disease was deWned as occurrence of UCC stage ¸T2.
At the beginning of the study the individual risk of recur-
rence was calculated according to the EORTC risk tables
[3], utilising the pathology results of TURBT. Further statis-
tical analyses were descriptive, with frequencies and gra-
dings, and appropriate spread and central values used.
Statistical analyses were performed in SPSS version 16.0.
Results
Patient and tumour characteristics
A total of 46 patients were enrolled in the study; 42 were
male and 4 were female. The age of patients ranged from
37 to 93 years (median 67.5). The patient characteristics
including six prognostic factors and calculated recurrence
scores according to the EORTC risk tables and prior adju-
vant intravesical therapy are shown in Table 1 [3].
Safety
Side-eVects have been described in detail before [7]. In
short, side-eVects did not exceed NCI-CTC grade 3. In 15
patients apaziquone treatment was postponed for 1 week
due to local side-eVects, but there was no need to lower the
dose of apaziquone to 2 mg/40 ml in any patient. During
the 6–24 months FU period one patient had grade 1–2
(probably related) lower abdominal pain up to 16 months
FU, and one patient had grade 1 (possibly related) dysp-
noea/pulmonary oedema up to 12 months FU. Both patients
recovered without further therapy. No clinical meaningful
changes were found by blood chemistry or urinalysis.
EYcacy
Our analysis 2–4 weeks post treatment showed a histologi-
cal CR in 30 of 45 patients (66.7%), or CR in 31 of 46
patients (67.4%, one patient refused biopsy of a ‘CR’ on
cystoscopy) [7].
For the current analysis, the FU period concerns 31 CR
patients. Two patients dropped out at 6 months FU; one
patient refused further cystoscopies, and one patient under-
went major surgery for a rectum carcinoma. At 24 months
FU, 49.5% of the CR patients were recurrence-free without
further instillations (Table 2). The median duration of
response was 18 months. None of the CR patients showed
progression to muscle invasive disease. Of 15 NR patients,
only 2 patients received Bacille Calmette-Guérin (BCG) ins-
tillations after TURBT; both patients had a recurrence at 6
and 9 months of FU, respectively. Because most patients in
the NR group did not receive further treatment, we also per-
formed ITT-analysis for these patients. At 24 months FU,
26.7% of the NR patients were recurrence-free (Table 2).
One NR patient had progression to T2 disease at 18 months
FU. Kaplan–Meier curves for time-to-recurrence are pre-
sented in Fig. 1 (log rank test, P = 0.155). When the CR and
NR patients are combined, the overall recurrence-free sur-
vival of patients with NMIBC treated with intravesical ins-
tillations of apaziquone is 18/46 (39%) after 2 years of FU.
Discussion
This study describes the eYcacy of six weekly instillations
of apaziquone after a complete ablative response for
patients with intermediate- and high-risk NMIBC, with
2 years of FU.340 World J Urol (2009) 27:337–342
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In this study, the CR rate of 67%, 2–4 weeks after the
last apaziquone instillation was superior to most marker
lesion studies performed with other (neo-) adjuvant drugs
(discussed in [7]). A marker lesion study represents an
excellent, safe method to test the ablative eYcacy of a
given treatment, with rates of progression to muscle inva-
sive disease of <1% [12]. Marker lesion studies are recom-
mended before embarking on any prophylactic study to
avoid treatment with an ineVective agent [13,  14]. Only
three studies also report about ‘long-term’ drug eYcacy in a
small number of CR patients [15–17]. Brausi et al. [15],
randomised patients with intermediate-risk NMIBC for
either 40 mg of MMC or electromotive drug administration
(EMDA)/MMC for 8 weeks, and obtained a CR in 41.6 and
40% of patients, respectively. Only two of Wve MMC-treated
patients with a CR were recurrence-free after 11 months,
and Wve of seven EMDA/MMC-treated patients with a CR
after a mean FU of little more than a year. Newling et al.
[16], treated patients with refractory UCC with or without
CIS of the bladder with six courses of 800 mg valrubicin,
and obtained a histological CR in 18/39 (46%) patients.
Their estimate of the mean time-to-recurrence was
248 days for CR and NR together, and 5 of 39 (12.8%)
patients remained recurrence-free after the FU period of
2 years. MaVezzini et al. [17], treated patients with low-
and intermediate-risk NMIBC with 2,000 mg of gemcita-
bine for 4 weeks, and obtained a CR in 13 of 28 (46.4%)
patients. Of the 28 (67.8%) patients, 19 experienced a
recurrence within the Wrst year. In comparison to other
drugs used in marker lesion studies where also longer term
Table 1 Six prognostic factors 
in accordance with the EORTC 
risk tables, calculated recurrence 
scores [3] and prior adjuvant 
intravesical therapy categorised 
for patients with CR and NR
Calculation of EORTC recurrence score CR NR
Variable Weight Number of 
patients
Mean 
(spread)
Number of 
patients
Mean 
(spread)
Number of tumours
Single 0 NA 3.5 (2–10) NA 4.2 (2–8)
2–7 3 29 14
¸86 2 1
Tumour size
<3 cm 0 26 NAa 12 NAa
¸3c m 3 5 3
Prior recurrence rate
Primary 0 8 3.1 (0–13)b 1 3.7 (0–11)b
·1 rec/year 2 16 9
>1 rec/year 4 7 5
T category
Ta 0 26 NA 12 NA
T1 1 5 3
Grade
G1 0 7 NA 4 NA
G2 1 23 11
G3 2 1c NA
CIS
No 0 31 NA 15 NA
Yes 1 NA NA
Recurrence score 0 NA 6.6 (4–10) NA 7.4 (5–11)
1–4 5 0
5–9 25 13
10–17 1 2
Prior adjuvant intravesical therapy
No therapy 13 0 4 0
Chemotherapy 11 1.5 (1–3)d 6 1.3 (1–2)d
BCG 1 1d 00 d
BCG and chemotherapy 6 4.8 (2–5)d 5 3.6 (2–5)d
CR complete response, NR no 
response, NA not applicable, CIS 
carcinoma in situ
a It was possible to estimate the 
maximum tumour size < or 
¸3 cm, but not to measure every 
single tumour
b Number of previous occur-
rences
c Formally ineligible, approved 
by principal investigator
d Number of courses of adjuvant 
intravesical therapyWorld J Urol (2009) 27:337–342 341
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FU was reported, the 2-year recurrence-free rate in our
study (49.5% in the CR group and 39% in the whole group)
represents a good result. The low percentage of recurrence-
free patients from the reported marker lesion studies might
be explained by the recruitment of patients with a high risk
of recurrence: these patients obviously had multiple
tumours, and often failed previous intravesical therapy.
We also calculated probabilities of recurrence according
to the EORTC risk Table [3], which were based on an anal-
ysis of 2,596 NMIBC patients who were treated between
1979 and 1989, but treatment of NMIBC at that time obvi-
ously diVered from the current NMIBC guidelines [1, 2].
Twenty percent of patients from the analysis initially
received no treatment, <10% received an immediate instil-
lation of chemotherapy, a second-look TURBT was not
performed in high-risk patients, and BCG was given with-
out maintenance instillations. Therefore, the predicted
recurrence and progression rates of the risk tables might be
higher compared to current clinical practice. Nevertheless,
the reported restrictions are by approximation also applica-
ble to the patients in our study. For patients with a risk
score of 1–4, 5–9 and 10–17, the corresponding probabili-
ties of recurrence after 2 years are 34, 51 and 71%, respec-
tively. In our study, the majority of patients (38 of 46,
82.6%) had a risk score of 5–9 (Table 1) with a 51% proba-
bility of recurrence at 2 years of FU. The overall recur-
rence-free survival at 2 years FU after apaziquone
treatment was 18/46 (39%). This seems to be worse than
the predicted probabilities of recurrence by the EORTC.
However, it is important to realise that most of our patients
with NR underwent TURBT without further prophylactic
treatment, which otherwise would have been given as part
of current routine treatment and would have inXuenced
clinical outcome. Furthermore, the failure of the NR
patients to respond to at least one kind of intravesical ther-
apy (in this case apaziquone) may increase the risk of recur-
rence for these patients. Therefore, the recurrence-free
survival with prophylactic treatment is expected to be
higher than 39%. Sub-analyses were performed between
the EORTC recurrence score groups, but the 1–4 and 10–17
groups were too small to note any signiWcant diVerences
with regard to treatment response. Of note: ‘all’ Wve
patients with a score of 1–4 had a CR to apaziquone treat-
ment.
As discussed, it is diYcult to compare our results with
results from literature and the EORTC tables. It is diYcult
to predict whether the good CR-rate of 67% at 3 months FU
also is an indication of a long-term eVect in preventing
recurrences. Apparently, the diVerence in recurrence-free
survival between the CR and NR groups (Fig. 1) is already
present from FU month 6, which does not support an ongo-
ing protective eVect in CRs.
Conclusions
After six apaziquone treatments, the CR of the marker
lesion in 67% of patients was followed by a recurrence-free
rate of 56.5% at 1-year FU, and 49.5% at 2-year FU. These
long-term results are good in comparison with long-term
results of other ablative studies, and appear to approach the
probabilities of recurrence according to the EORTC risk
tables, which are derived from studies with prophylactic
intent.
Table 2 Per FU-visit the number of patients and the recurrence-free
survival for the CR and NR group
FU follow-up, CR complete response, NR no response
a After TURBT, recurrence-free survival is set to 100% for the NR
patients at 3 months FU
FU 
month
Marker lesion response
CR NR
No. of 
patients
Recurrence-free 
survival (%)
No. of 
patients
Recurrence-free 
survival (%)a
3 31 100 15 100
6 21 74.2 9 60
9 19 67.1 8 53.3
12 16 56.5 6 40
18 14 49.5 4 26.7
24 14 49.5 4 26.7
Fig. 1 Time-to-recurrence by response group342 World J Urol (2009) 27:337–342
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